Anlon Healthcare Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Anlon Healthcare Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Profit Cash Ratio: Over the last 3 years, every ₹100 of reported profit came with ₹-179 of operating cash. Lower than almost all Healthcare companies in India.
- Cash Locked Ratio: For every ₹100 of sales, ₹91 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹38 tied up three years earlier. More money tied up than almost all Healthcare companies in India.
- Self-Funding Ratio: Over the last 3 years operating cash was negative while the company kept spending on investment (capex). Lower than 98% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹-179Over the last 3 years, every ₹100 of reported profit came with ₹-179 of operating cash.
Lower than almost all Healthcare companies in India.
Self-Funding Ratio
-2.6×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 98% of Healthcare companies in India.
Cash Locked Ratio
₹91For every ₹100 of sales, ₹91 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹38 tied up three years earlier.
More money tied up than almost all Healthcare companies in India.
Growth quality
Steadiness Ratio
2/3 · 3/3Sales grew in 2 of the last 3 years; profit grew in 3 of 3.
Steadier than 53% of Healthcare companies in India.
Growth Efficiency Ratio
₹38Sales grew 52% in 3 years; of every extra ₹100 of sales, ₹38 became extra profit.
Higher than 86% of Healthcare companies in India.
Asset Productivity Ratio
+52% / +235%In 3 years sales changed by +52% while total assets changed by +235%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
-2.1×Operating cash was negative last year, while some debt falls due within a year.
Lower than 97% of Healthcare companies in India.
Cash Cushion Ratio
−3%Debt, after subtracting cash, equals 3% of its market value (net debt).
Lower than 56% of Healthcare companies in India.
Tangible Assets Ratio
100%Of every ₹100 the company owns, ₹100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 93% of Healthcare companies in India.
Tangible Net Worth Ratio
100%Of every ₹100 of net worth, ₹100 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 92% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Anlon Healthcare Limited owes ₹0.32 for every ₹1 it owns. Net profit rose 39% in the year to Mar 2026, and grew 70% a year on average over 3 years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
37.6Investors pay ₹37.6 for every ₹1 of Anlon Healthcare Limited's yearly profit, higher than 53% of Healthcare companies in India.
P/B ratio
5.90The share price is 5.90 times Anlon Healthcare Limited's book value per share, higher than 65% of Healthcare companies in India.
Market cap
₹1,359 CrThe total market value of all of Anlon Healthcare Limited's shares at today's price (share price × number of shares), smaller than 74% of Healthcare companies in India. PosiCap size class: Mini Cap.
Net worth (book value)
₹230 CrWhat Anlon Healthcare Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹4.33Net worth divided by the number of shares. The share price of ₹25.56 is 5.9 times this, which is the P/B above.
Return on equity (ROE)
13.3%Anlon Healthcare Limited earned 13.3% on its shareholders' money over the last year, higher than 53% of Healthcare companies in India.
Owes vs Owns
0.32×Anlon Healthcare Limited owes ₹0.32 for every ₹1 it owns (low), lower than 63% of Healthcare companies in India.
Dividend yield
NoneAnlon Healthcare Limited does not currently pay a dividend.
Revenue growth
+43%Revenue rose 43% in the year to Mar 2026, and grew 15% a year on average over 3 years.
Profit growth
+39%Net profit rose 39% in the year to Mar 2026, and grew 70% a year on average over 3 years.
Profit margin
16.6%Anlon Healthcare Limited keeps ₹17 of every ₹100 of revenue as net profit.
Cash quality
-2.8×Cash from Anlon Healthcare Limited's business was -2.8× its reported profit in the year to Mar 2026 — the business used cash even though it reported a profit.
Interest cover
16.9×Anlon Healthcare Limited's operating profit covered its interest costs 16.9 times in the year to Mar 2026.
Cash vs debt
Net debtAnlon Healthcare Limited had ₹39 Cr more debt than cash (net debt) at Mar 2026.
Questions
What is Anlon Healthcare Limited's P/E ratio?
Investors pay ₹37.6 for every ₹1 of Anlon Healthcare Limited's yearly profit, higher than 53% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Anlon Healthcare Limited: ₹1,359 Cr ÷ ₹230 Cr (31 Mar 2026) = 5.9.
What is Anlon Healthcare Limited's return on equity?
Anlon Healthcare Limited earned 13.3% on its shareholders' money over the last year, higher than 53% of Healthcare companies in India.
How much does Anlon Healthcare Limited owe compared with what it owns?
Anlon Healthcare Limited owes ₹0.32 for every ₹1 it owns (low), lower than 63% of Healthcare companies in India.
Does Anlon Healthcare Limited pay a dividend?
No. Anlon Healthcare Limited does not currently pay a dividend.
Is Anlon Healthcare Limited's revenue growing?
Revenue rose 43% in the year to Mar 2026, and grew 15% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.